Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.
阿扎胞苷与选择性 FLT3 激酶抑制剂克雷诺拉尼联合使用，可破坏基质保护，并抑制伴有表观遗传突变的 FLT3-ITD AML 中残留白血病起始细胞的扩增。
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.21877
Garz Anne-Kathrin, Wolf Saskia, Grath Sonja, Gaidzik Verena, Habringer Stefan, Vick Binje, Rudelius Martina, Ziegenhain Christoph, Herold Sylvia, Weickert Marie-Theresa, Smets Martha, Peschel Christian, Oostendorp Robert A J, Bultmann Sebastian, Jeremias Irmela, Thiede Christian, Döhner Konstanze, Keller Ulrich, Götze Katharina S
